It is with great pleasure that I invite you to participate in this ESMO webinar that will focus on current and future strategies in the management of patients with oesophageal cancer.
This webinar aims to provide an overview of the best standard approach for patients with localised oesophageal cancer, practical considerations selecting optimal sequence of immune checkpoint inhibitors for the treatment of patients with advanced oesophageal cancer, as well as use of different predictive biomarkers to maximise benefit of immune checkpoint inhibitors.
We will begin with a lecture on optimal multimodality management of localised oesophageal cancer. Next, we have a lecture on the role of immune checkpoint inhibitors in the continuum of care for patients with advanced oesophageal cancer. Finally, we will present a clinical case and focus on the role of biomarkers for prognostication and prediction of benefit from immunotherapeutic approaches. The lectures will be followed by a live discussion where we will also answer questions from the audience.
The programme is designed to provide an overview of the latest evidence in the management of patients with oesophageal cancer, offer expert opinion exchange and provide some important considerations about future strategies in this field. I strongly encourage and invite you to register and join us all in this ESMO activity.
Prof. Andrés Cervantes
Hospital Clinic Universitario
Biomedical Research institute INCLIVA
University of Valencia